Neurooncol Adv 2023 Jan-Dec
Long-term outcomes with reduced-dose whole-brain radiotherapy and a stereotactic radiosurgery boost for primary central nervous system lymphoma.
Related Questions
New answer by Radiation Oncologist at University of Arizona (July 1, 2024)
For the sake of discussion, I will assume that this patient achieved a PR after a high-dose MTX regimen. If the patient is young (<60 yo) and has a good KPS (>70), I wou...
Could one de-escalate WBRT dose to <30-36 Gy if maintaining boost to residual disease to 45 Gy? How would you counsel patients on late toxicities f...
New answer by Radiation Oncologist at University Hospital Basel (January 26, 2025)
I principally agree with the comments by Prof. @Kelsey. Just some extra thoughts:
A patient with partial response to HD-MTX-R is very unlikely to achieve durable control of t...